Objective: Although present treatment programs for renal cell carcinoma (RCC) typically involve molecular-targeting drugs, interferon-alpha (IFN-a) remains an important therapeutic drug for this cancer. Methods: We evaluated the effect of adjuvant therapy in 508 patients with RCC following curative surgery. Patients were classified into one of the two categories based on the duration and the total dose of IFN-a treatment.
INTRODUCTION
Although present treatment programs for renal cell carcinoma (RCC) typically involve molecular-targeting agents (1), interferon-alpha (IFN-a) remains an important therapeutic drug in treating this cancer (2) .
Here, we performed a multivariate analysis of clinical variables in 508 patients with RCC to identify prognostic factors important for long-term survival. Further, we retrospectively investigated the effect of treatment with IFN-a on both cause-specific and disease-free survival in patients with RCC following curative resection.
PATIENTS AND METHODS
We retrospectively examined the medical records of 755 patients with RCC admitted to the Department of Urology at Hamamatsu University Hospital and affiliated hospitals between 1978 and 2004. We then identified the 508 patients diagnosed as pT1-2N0M0 as those with RCC following curative resection and evaluated the effect of adjuvant therapy with IFN-a in these patients.
Clinical characteristics of the 508 patients were gender, age, tumor laterality, Eastern Cooperative Oncology Group performance status (ECOG PS), mode of tumor discovery, C-reactive protein (CRP), T classification, cell type, histological grade, infiltration mode and venous invasion. The cut-off of CRP was based on the value of reference range in each hospital. Tumors were graded according to the criteria of the Japanese Urological Association (3) and the TNM system (4).
The Kaplan -Meier method was used to estimate survival rates. The log-rank test and Cox's proportional hazard model were used for univariate and multivariate analysis, respectively. Differences were considered statistically significant at P , 0.05. All analyses were conducted using StatView ver. 5.0J (SAS Institute Inc., Cary, NC, USA).
RESULTS
Of the 508 patients, the male-to-female ratio was 2.22. The mean patient age was 59.5 + 12.7 years (range 15 -86 (Fig. 1 ).
Patients were divided into two groups based on the most significant difference according to the analysis of causespecific survival rates ( Table 2 ). Univariate analysis showed that the prognostic factors significant for survival were age, mode of discovery, CRP, T classification and histological grade. Multivariate analysis showed that four of the factors (CRP, T classification, histological grade and age) were independent of prognosis, the odds ratios of which were 3.873, 3.067, 3.237 and 2.438, respectively.
With regard to disease-free survival, four prognostic factors (mode of discovery, CRP, T classification and infiltration mode) were found to be significant by univariate analysis (odds ratios 3.873, 3.067, 3.237 and 2.438, respectively) ( Table 3) , and two factors (CRP and T classification) were found to be independent of prognosis by multivariate analysis. In the present study, only CRP and T classification were significant prognostic factors in both cause-specific and disease-free survival.
Among the 508 patients who underwent curative resection, 480 underwent radical nephrectomy (including laparoscopic surgery in 27) and 28 had nephron-sparing surgery. Two hundred and fifty-three patients (49.8%) received adjuvant therapy by IFN-a and 255 (50.2%) without adjuvant therapy. This decision was made by the chief doctor based on examination of each patient.
During the follow-up period, 447 patients were alive, 28 died of cancer and 33 died of other diseases. Recurrence of RCC was seen in 43 patients (including lung only in 14, bone only in 10, multiple organs in 8 and opposite kidney in 3).
Univariate analysis showed that adjuvant therapy with IFN-a was not significantly associated with either cause- specific or disease-free survival ( Table 2, 3 ). On dividing the 253 patients treated with adjuvant IFN-a therapy into two subgroups based on duration of treatment (,12 or !12 months), the duration of IFN-a therapy was not found to be significantly correlated with cause-specific or disease-free survival ( Table 4 ). The 253 patients treated with adjuvant IFN-a therapy were also divided into two categories based on total dose of IFN-a. The median total dose in these patients was 180 Â 10 6 international units (IU) (range ¼ 6-4356 Â 10 6 IU). As shown in Table 4 , patients receiving a large total dose (!180 Â 10 6 IU) had a better prognosis for cancer-specific survival than those receiving a small dose (,180 Â 10 6 IU), although the same relationship was not seen with disease-free survival. With regard to the large-dose group, we also examined the relationship between these results and CRP and T classification, significant prognostic factors for survival. As depicted in Fig. 2 , the cause-specific survival among CRP-positive patients in the large-dose group was better than that of CRP-positive patients in the small-dose group. On dividing T classification into T1 and T2, the cause-specific survival among T1 status in the largedose group was better than that of T1 status in the smalldose group. With regards to T2 status, the large-dose group appeared to be a trend toward better prognosis. Adjuvant therapy with IFN-a after curative resection in T1-2N0M0 patients was not significantly associated with either causespecific or disease-free survival in our study.
DISCUSSION
Our study conducted in 508 patients with RCC who underwent curative resection found that IFN-a therapy was not significantly associated with either cause-specific or diseasefree survival. However, patients receiving a total IFN-a 312 Efficacy of adjuvant interferon-a therapy after curative resection in RCC exposure of !180 Â 10 6 IU had a better prognosis than those exposed to ,180 Â 10 6 IU. Molecular-targeting drugs now widely used in the treatment of advanced RCC, whereas the use of IFN therapy is gradually decreasing. However, IFN is safer and less expensive than molecular-targeting drugs. We are, moreover, familiar with IFN. Taken together, the usefulness of adjuvant IFN therapy in the treatment of RCC, particularly its effectiveness, duration of treatment and the volume of IFN, must be reconsidered.
Several studies have determined prognostic factors of RCC by multivariate analysis. Among prognostic factors, tumor stage, nuclear grade, DNA ploidy and nuclear morphometry, tumor size, lymph node metastasis, distant metastasis, tumor histology and venous invasion are generally thought to be important prognostic factors, whereas laboratory values such as an elevated erythrocyte sedimentation rate, hypercalcemia, anemia, elevated levels of lactate dehydrogenase, CRP and immunosuppressive acidic protein are associated with progression in RCC (5 -11), and several recent reports have cited the influence of CRP presence in particular.
Masuda et al.'s (12) report documenting the prognostic factors of 320 patients with RCC treated at our institution between 1978 and 1995 found that age, N classification and M classification were the most important prognostic factors conducive to predicting long-term survival of these patients. A portion of these records were also included in the present study when we reviewed pT1-2N0M0 RCC patients who underwent curative surgery, with CRP and T classification as significant prognostic factors.
Gotoh et al. (13) investigated the long-term efficacy of adjuvant therapy with IFN-a in T1-3bN0M0 patients who underwent curative resection. Subjects were divided into three groups according to the IFN-a administration duration ( 6 months, from 6 months to ,1 year and !1 year); however, results found no statistical significance with either cause-specific or disease-free survival. Similarly, we also found no significance between administration duration and survival. Basting et al. (14) reported that adjuvant therapy with IFN-a provided no significant benefit in the treatment of non-metastatic RCC and that tumor stage was not a suitable factor for selecting patients who may potentially respond well to IFN-a therapy. Migliari et al. (15) also studied the efficacy of adjuvant chemo-immunotherapy combining IFN-a and vinblastine in pT2-3N0M0 patients after curative resection, but found no significant benefit in the treatment.
With regard to the present study, we evaluated the efficiency of adjuvant therapy with IFN-a for pT1-2N0M0 RCC patients after curative resection. Although the therapy failed to exhibit a significant effect on either cause-specific or disease-free survival, patients in our study population receiving a total IFN-a administration of !180 Â 10 6 IU had a better prognosis than those receiving ,180 Â 10 6 IU. Further, CRP-positive patients also appeared to enjoy a better prognosis. Careful examination of these data suggests that large-dose adjuvant IFN therapy may improve prognosis for patients with localized RCC.
Findings from the present study were similar to those of previous studies, showing that adjuvant IFN therapy was not effective as a prophylactic treatment for RCC patients after curative surgery. However, our findings do suggest that large-dose IFN-a treatment may improve the prognosis of RCC patients after curative resection, particularly among CRP-positive patients. New possibilities for the use of IFN-a therapy merit investigation, while simultaneously continuing current use of molecular-targeting drugs, such as sorafenib, sutent and other agents in the future. Missing data: duration, n ¼ 10; total dose, n ¼ 28. IU, international units.
